Does Capturing Debris During TAVR Prevent Strokes?
NEJM 387:1318-1319, Carroll, J.D. & Saver, J.L., 2022
The SANAD II Study of the Effectiveness and Cost-Effectiveness of Valproate Versus Levetiracetam for Newly Diagnosed Generalised and Unclassifiable Epilepsy: An Open-Label, Non-Inferiority, Multicentre, Phase 4, Randomised Controlled Trial
Lancet 397:1375-1386, Marson, A.,et al, 2021
Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke
NEJM 384:2081-2091,2154, Whitlock, R.P.,et al, 2021
US Case Reports of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Ad26.COV2.S Vaccination, March 2 to April 21, 2021
JAMA 325:2448-2456,2445, See, I.,et al, 2021
Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Pharmacologic Treatment for Pediatric Migraine Prevention
Neurol 93:500-509, Oskoui, M.,et al, 2019
Evidence-Based Management of Patent Foramen Ovale in Patients with Ischemic Stroke
JAMA Neurol 75:147-148, Kamel, H., 2018
Antiplatelet and Anticoagulant Agents for Secondary Prevention of Thromboembolic Events in People with Antiphospholipid Syndrome
Stroke 49:e41-e42, Bala, M.M.,et al, 2018
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Non-Specific Low Back Pain
Lancet 389:736-747, Maher, C.,et al, 2017
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Infective Endocarditis
Lancet 387:882-893, Cahill, T.J. & Prendergast, B.D., 2016
Should Atrial Fibrillation Patients with only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?
Stroke 47:1831-1836, Fauchier, L.,et al, 2016
Closure Versus Medical Therapy for Preventing Recurrent Stroke in Patients with Patent Foramen Ovale and a History of Cryptogenic Stroke or Transient Ischemic Attack
Stroke 47:e188-e189, Li, J.,et al, 2016
Review of the Utility of Prophylactic Anticonvulsant Use in Critically Ill Patients with Intracerebral Hemorrhage
Stroke 47:2666-2672, Gilmore, E.J.,et al, 2016
Evidence-Based Guideline: Management of an Unprovoked First Seizure in Adults
Neurol 84:1705-1713, Krumholz, A.,et al, 2015
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
NEJM 373:823-833, Douketis,J.D.,et al, 2015
Multidisciplinary Consensus on Assessment of Unruptured Intracranial Aneurysms
Stroke 45:1523-1530, Etminan, N.,et al, 2014
Stroke Patients with Suspected Atrial Fibrillation Should be Started on Anticoagulation Pending the Results of Long-Term Cardiac Monitoring
Stroke 44:298-299,302, Diener, H., 2013
Stroke Patients with Suspected Atrial Fibrillation Should NOT be Started on Anticoagulation WHILE AWAITING the Results of Long-Term Cardiac Monitoring
Stroke 44:300-301,302, Katsnelson, M. & Sacco, R., 2013
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Management of Antithrombotic Therapy in Patients Undergoing Invasive Procedures
NEJM 368:2113-2124, Baron, T.,et al, 2013
Pacemaker of Defibrillator Surgery without Interruption of Anticoagulation
NEJM 368:2084-2093, Birnie, D.,et al, 2013
Aggressive Medical Therapy Alone is Not Adequate in Certain Patients with Severe Symptomatic Carotid Stenosis
Stroke 44:2955-2956, Brown, M.M., 2013
Aggressive Medical Therapy Alone is Adequate in Certain Patients with Severe Symptomatic Carotid Stenosis
Stroke 44:2957-2958, Chaturvedi, S.,et al, 2013
Left Atrial Catheter Ablation and Ischemic Stroke
Stroke 43:265-270, Haeusler, K.G.,et al, 2012
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012
Antiplatelets vs Anticoagulation for Dissection
Neurol 79:686-689, Kennedy, F.,et al, 2012
Preventive Antibiotics in Acute Stroke
Stroke 43:e113-e114, Westendrop, W.F.,et al, 2012
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011
Treatment of Unruptured Cerebral Aneurysms: Cause for Concern?
AJNR 32:1076-77, Molyneux, A.J., 2011
Patient Outcomes are Better for Unruptured Cerebral Aneurysms Treated at Centers that Preferentially Treat with Endovascular Coiling: A Study of the National Inpatient Sample 2001-2007
AJNR 32:1065-1070, 1076, Brinjiikii, W.,et al, 2011
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010
Transoesophageal Echocardiography in Patients with Acute Stroke with Sinus Rhythm and No Cardiac Disease History
JNNP 81:412-415, Cho,H.-J., et al, 2010
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage
Stroke 41:2108-2129, Morgenstern,L.B.,et al, 2010
Study Design of the CLOSURE I Trial: A Prospective, Multicenter, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex Septal Closure System Versus Best Medical Therapy in Patients With Stroke or TIA Due to Presumed Paradoxical Embolism Through a PFO
Stroke 41:2872-2883, Furlan,A.J.,et al, 2010
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? No
Stroke 40:1944-1945,1946, Fisher,M., 2009
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? Yes
Stroke 40:1942-1943,1946, Furlan,A.J., 2009
Recurrent Cerebral Ischemia in Medically Treated Patent Foramen Ovale: A Meta-Analysis
Neurol 73:89-97,84, Almekhlafi,M.A.,et al, 2009
Risk of Dementia and AD with Prior Exposure to NSAIDs in an Elderly Community-Based Cohort
Neurol 72:1899-1905,1884, Breitner,J.C.S.,et al, 2009
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinsons Disease
NEJM 361:1268-1278, 1304, Olanow,C.,et al, 2009
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: No
Stroke 40:3161-3162, 3163, Strauss,M. &Hall,A., 2009
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: Yes
Stroke 40:3159-3160, 3163, Hackam,D., 2009
The Value of Specifying Brand-Name Antiepileptic Drugs
Arch Neurol 66:1415-1416, 1418, Ng,Y., 2009
Generic Anticonvulsant Use in Children: Do We Have Evidence to Recommend Brand Formulations?
Arch Neurol 66:1417-1418, Hamiwka,L., 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009